查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1855044

干细胞製造的全球市场:各产品，各用途，各流通管道，各终端用户，各地区-市场规模，产业动态，机会分析，预测(2025年～2033年)

Global Stem Cell Manufacturing Market: By Product, Application, Distribution Channel, End Users, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 421 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

在临床研究取得重大成功以及新疗法获准的推动下，干细胞製造领域正经历快速发展，这些成功和新疗法正在改变再生医学领域。这些进展验证了干细胞技术的治疗潜力，激发了研究人员、投资者和医疗保健提供者的兴趣和信心。因此，该市场经历了显着成长，预计到 2024 年市场规模将达到约 242.6 亿美元。这一成长趋势预计将持续，市场估计和预测显示，到 2033 年，该市场规模将达到 654.9 亿美元。在预测期（2025-2033 年）内，该市场复合年增长率 (CAGR) 为 11.96%，展现出强劲的发展势头和不断扩大的行业成长机会。

这项快速扩张主要得益于策略性外包的激增以及大型製药公司投资的增加。这些合作和资金投入对于解决长期存在的生产瓶颈至关重要，这些瓶颈一直限制着干细胞疗法的规模化和成本效益。透过与专业的合约生产组织 (CMO) 合作并投资于尖端生产技术，製药公司正在增强其生产能力并简化流程。这种策略性外包方法不仅缓解了营运限制，还加快了疗法的商业化和全球市场上市速度。

值得关注的市场动态

干细胞生产市场的关键参与者正在进行大量投资以满足预期需求。产业领导者 Lonza 已在其位于 Vacaville 的工厂投资约 5 亿瑞士法郎，该工厂目前已拥有约 33 万公升的生物反应器产能。这项重大投资体现了龙沙公司致力于扩展其製造基础设施，以满足再生医学和细胞疗法开发商日益增长的需求的战略重点。

同样，赛默飞世尔科技公司也采取大胆举措，加强其研发和製造能力。该公司正在研发领域投资14亿美元，光在纽约市就将其製造规模扩大了45,000多平方英尺。此次扩张是其更广泛策略的一部分，旨在提高生产效率、加速创新并支持其干细胞疗法产品线的扩展。赛默飞世尔对研发和基础设施的双重投入，凸显了将科学进步与可扩展製造解决方案结合的重要性。

此外，龙沙公司正在休士顿开发一座30万平方英尺的新工厂，进一步凸显了该产业积极扩大产能的策略。此次扩建不仅体现了龙沙致力于满足未来商业需求的决心，也反映了干细胞生产市场建设能够实现大规模生产的先进设施的更广泛趋势。

核心驱动因素

慢性病的日益增多是推动再生医学市场（包括干细胞生产）成长的关键因素。糖尿病、心血管疾病、神经退化性疾病和自体免疫疾病等慢性病在全球日益普遍，给医疗保健系统和患者带来了沉重的负担。传统疗法通常侧重于症状管理而非治愈，因此，人们迫切需要能够修復或替换受损组织并恢復正常功能的创新疗法。再生医学可望利用人体自身的癒合机制，为解决这些尚未满足的医疗需求提供了一条充满希望​​的途径。

新商机趋势

将人工智慧 (AI) 整合到预测性品质控制 (QC) 中，预计将为干细胞生产市场带来变革性机遇，显着提高效率和产品可靠性。传统的干细胞生产品质控制方法通常依赖人工检查和定期抽样，这些方法耗时且容易出现误差。相较之下，基于人工智慧的系统利用先进的演算法，能够即时处理大量数据，从而实现对生产过程的持续监控和潜在问题的早期检测。这种能力不仅提高了品质评估的准确性，还降低了批次缺陷的风险，并提高了整体生产产量和一致性。

优化障碍

干细胞疗法的高昂生产成本和固有的生产复杂性构成了重大挑战，可能会阻碍这些疗法的广泛应用并减缓市场成长。干细胞生产涉及复杂的流程，需要严格遵守品质标准、无菌环境和专用设备。这些因素推高了生产成本，可能导致许多医疗机构和患者难以负担治疗费用。这些成本驱动的经济障碍限制了治疗的可近性和普及，尤其是在预算有限的地区和医疗系统中。

目录

第1章 调查架构

  • 调查目的
  • 产品概要
  • 市场区隔

第2章 调查手法

  • 定性调查
    • 一级资讯来源·二级资讯来源
  • 定量调查
    • 一级资讯来源·二级资讯来源
  • 初步调查受访者的明细:各地区
  • 调查的前提条件
  • 市场规模·估计
  • 资料的三角测量

第3章 摘要整理:干细胞製造的全球市场

第4章 干细胞製造的全球市场概要

  • 产业价值链分析
    • 材料供应商
    • 製造商
    • 销售商
    • 终端用户
  • 产业展望
    • 全球GDP与医疗保健基础设施
    • 製药、生物技术和CRO/CDMO的成长
    • 慢性病负担加重
    • 从干细胞实验室研究到核准临床疗法的转变
    • 干细胞生产流程与新兴技术
    • 常用干细胞型
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商业者的威胁
    • 竞争的程度
  • 市场动态和趋势
    • 促进因素
    • 课题
    • 机会
    • 主要趋势
  • 市场成长与展望
    • 市场收益估计·预测，2020年～2033年
    • 价格趋势分析
  • 竞争仪表板
    • 市场集中率
    • 企业占有率分析(金额%)、2024年
    • 竞争的製图和基准

第5章 干细胞製造的全球市场分析:各产品类型

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 干细胞线
    • 消耗品和套件
    • 设备
    • 软体和服务

第6章 干细胞製造的全球市场分析:各用途

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 研究用途
    • 临床用途
    • 细胞·组织银行

第7章 干细胞製造的全球市场分析:各流通管道

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 直销
    • 经销商

第8章 干细胞製造的全球市场分析:各终端用户

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • CRO，製药，生物科技企业
    • 学术·研究机关
    • 医院·手术中心
    • 细胞·组织银行
    • 其他的用户(再生医疗Start-Ups，诊断公司)

第9章 干细胞製造的全球市场分析:各地区

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第10章 北美的干细胞製造市场分析

第11章 欧洲的干细胞製造市场分析

第12章 亚太地区的干细胞製造市场分析

第13章 中东·非洲的干细胞製造市场分析

第14章 南美的干细胞製造市场分析

第15章 企业简介

  • Thermo Fisher Scientific
  • Lonza
  • nacalai
  • BioRad
  • Merck
  • FujiFilm
  • CellGenix
  • Teknova
  • Sartorius
  • Stemcell Technologies
  • Miltenyi Biotec
  • Eppendorf
  • Beckman Coulter
  • Takara Bio
  • Bio-Techne
  • PromoCell
  • Wellsky
  • BD
  • Corning Life Sciences
  • HiMedia
  • REPROCELL
  • Other Prominent Players

第16章 附录

简介目录
Product Code: AA09251517

The stem cell manufacturing landscape is evolving rapidly, fueled by significant clinical trial successes and the approval of new therapies that are transforming the regenerative medicine field. These advancements have validated the therapeutic potential of stem cell technologies, driving increased interest and confidence among researchers, investors, and healthcare providers. As a result, the market has experienced substantial growth, with its valuation reaching approximately US$ 24.26 billion in 2024. This upward trajectory is expected to continue, with projections estimating the market will expand to a remarkable US$ 65.49 billion by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 11.96% during the forecast period from 2025 to 2033, underscoring the strong momentum and expanding opportunities within the industry.

A key factor contributing to this rapid expansion is the surge in strategic outsourcing and increased investments from major pharmaceutical companies. These collaborations and financial commitments are crucial in addressing longstanding manufacturing bottlenecks that have challenged the scalability and cost-effectiveness of stem cell therapies. By partnering with specialized contract manufacturing organizations (CMOs) and investing in cutting-edge production technologies, pharmaceutical players are enhancing manufacturing capacity and streamlining processes. This strategic outsourcing not only alleviates operational constraints but also accelerates the pace at which therapies can be commercialized and brought to market on a global scale.

Noteworthy Market Developments

Leading corporations in the stem cell manufacturing market are making substantial investments to position themselves for anticipated future demand, signaling a robust commitment to scaling production capabilities and advancing the field. Lonza, a key player in the industry, is investing approximately 500 million Swiss francs into its Vacaville facility, which already features an impressive bioreactor capacity of around 330,000 liters. This significant financial commitment reflects Lonza's strategic focus on expanding its manufacturing infrastructure to meet the growing needs of regenerative medicine and cell therapy developers.

Similarly, Thermo Fisher Scientific is making bold moves to enhance its research and manufacturing capabilities. The company is investing $1.4 billion in research and development, alongside expanding its manufacturing footprint by more than 45,000 square feet in New York alone. This expansion is part of a broader strategy to increase production efficiency, accelerate innovation, and support a growing pipeline of stem cell therapies. Thermo Fisher's commitment to both R&D and physical infrastructure highlights the critical importance of integrating scientific advancement with scalable manufacturing solutions.

Adding to this momentum, Lonza is also developing a new 300,000-square-foot facility in Houston, further emphasizing the industry's aggressive approach to scaling capacity. This expansion not only demonstrates Lonza's dedication to meeting future commercial demand but also reflects a broader trend within the stem cell manufacturing market toward building state-of-the-art facilities capable of supporting high-volume production.

Core Growth Drivers

The rising prevalence of chronic diseases is a significant factor driving the growth of the regenerative medicine market, including stem cell manufacturing. Chronic illnesses such as diabetes, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions have become increasingly common worldwide, placing a substantial burden on healthcare systems and patients alike. Traditional treatment options often focus on managing symptoms rather than offering curative solutions, leading to a growing demand for innovative therapies that can repair or replace damaged tissues and restore normal function. Regenerative medicine, with its potential to harness the body's own healing mechanisms, presents a promising avenue for addressing these unmet medical needs.

Emerging Opportunity Trends

The integration of artificial intelligence (AI) into predictive quality control (QC) represents a transformative opportunity for the stem cell manufacturing market, promising to significantly enhance efficiency and product reliability. Traditional QC methods in stem cell manufacturing often rely on manual inspections and periodic sampling, which can be time-consuming and prone to inconsistencies. In contrast, AI-driven systems leverage advanced algorithms capable of processing vast amounts of data in real time, allowing for continuous monitoring and early detection of potential issues during the manufacturing process. This capability not only improves the accuracy of quality assessments but also reduces the risk of batch failures, thereby increasing overall manufacturing yield and consistency.

Barriers to Optimization

High manufacturing costs and the inherent complexity of producing stem cell therapies pose significant challenges that could impede the widespread adoption of these treatments and potentially slow market growth. Stem cell manufacturing involves intricate processes that demand strict adherence to quality standards, sterile environments, and specialized equipment. These factors contribute to elevated production expenses, which in turn can make therapies prohibitively expensive for many healthcare providers and patients. The financial barrier created by these costs limits accessibility and adoption, especially in regions or healthcare systems with constrained budgets.

Detailed Market Segmentation

By Product Type, the consumables and kits segment holds a crucial position within the stem cell manufacturing market, commanding a substantial revenue share of 42.51%. This segment forms the backbone of the entire industry, as consumables and kits are indispensable at every stage of the stem cell lifecycle-from initial research and development to scale-up and commercial production. The recurring nature of demand for these products stems from their essential role in maintaining cell viability, supporting cell growth, and ensuring the precision required for consistent manufacturing outcomes. Without reliable and high-quality consumables, the entire process of stem cell manufacturing would face significant challenges, making this segment foundational to the industry's overall success.

By Distribution Channel, the direct sales channel dominates the stem cell manufacturing market, generating over 69.93% of the total market revenue. This overwhelming share is largely attributed to the highly sensitive and complex nature of stem cell products, which demand specialized handling and distribution processes. Unlike conventional pharmaceutical products, stem cell therapies are living biological materials that require precise conditions to maintain their viability and therapeutic efficacy. The intricate nature of these products necessitates direct interaction between manufacturers and end-users, such as hospitals, clinics, and research institutions, ensuring strict quality control and compliance with regulatory standards throughout the supply chain.

By End Users, Pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are controlling the largest 44.67% market share. There are a few companies that hold the dominant position in the market, but they are collectively the commercial engine of the industry. These entities in the stem cell manufacturing market possess the financial resources, infrastructure, and regulatory expertise necessary to navigate the long and expensive path from research to commercialization.

By Application, the clinical applications segment holds a commanding position within the stem cell manufacturing market, accounting for 52.32% of the total market share. This significant share reflects the critical role clinical applications play in transforming the scientific potential of stem cell research into real-world medical treatments. As the field of regenerative medicine continues to advance, clinical applications serve as the primary avenue through which promising laboratory discoveries are translated into therapies that can improve patient outcomes. The emphasis on clinical use underscores the growing confidence in stem cell technologies as viable treatment options for a range of diseases and conditions.

Segment Breakdown

By Product

  • Stem Cell Lines
  • Mesenchymal Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Induced Pluripotent Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Hematopoietic Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Embryonic Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Neural Stem Cells
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Others
  • Differentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Undifferentiated
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Consumables and Kits
  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • Consumables and Kits

By Type

  • Culture Media
  • Growth Factors & Cytokines
  • Culture ware and Vessels
  • T-Flasks
  • Vials
  • Cell Culture Dishes / Multi-Well Plates
  • Cell Culture Bags
  • Others
  • Others

By Application

  • Research Applications
  • Disease Modelling
  • Drug Discovery & Toxicology Testing
  • Others
  • Clinical Applications
  • Autologous Therapies
  • Allogeneic Therapies
  • Cell & Tissue Banking
  • Instruments
  • Bioreactors & Cell Expansion Systems
  • Cell Sorters & Separation Devices
  • Flow Cytometers & Analysers
  • Software and Services

By Application

  • Research Applications
  • Disease Modelling
  • Drug Discovery & Toxicology Testing
  • Others
  • Clinical Applications
  • Autologous Therapies
  • Allogeneic Therapies
  • Cell & Tissue Banking

By Distribution Channel

  • Direct Sales
  • Distributors

By End User

  • CROs, Pharmaceutical and Biotechnology Companies
  • Academic & Research Institutions
  • Hospitals & Surgical Centres
  • Cell & Tissue Banks
  • Other Users (Regenerative Medicine Startups, Diagnostic Firms)

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Cambodia
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America stands out as the undisputed global leader in the stem cell manufacturing market, propelled by a strong blend of well-established regulatory frameworks, significant public funding, and a thriving biotechnology ecosystem. The region's dominance is anchored by its ability to create a conducive environment for research, development, and commercialization of stem cell technologies. Regulatory agencies in the United States and Canada have developed clear and structured pathways that facilitate the approval and oversight of stem cell products, giving companies the confidence to invest heavily in innovation and scale-up manufacturing capabilities. This regulatory clarity is a critical factor that distinguishes North America from other regions, reducing uncertainties and accelerating the time to market for new therapies.
  • The market's anticipated share of over 49.58% by 2033 highlights North America's commanding presence in the industry. This leading position is reinforced by the substantial financial resources directed toward stem cell research and manufacturing infrastructure. Both federal and state governments in the U.S. have launched initiatives and funding programs that support biotechnology ventures, clinical trials, and manufacturing advancements. These investments not only stimulate industry growth but also foster collaboration between academia, private companies, and healthcare providers.

Leading Market Participants

  • Thermo Fisher Scientific
  • Lonza
  • nacalai
  • BioRad
  • Merck
  • FujiFilm
  • CellGenix
  • Teknova
  • Sartorius
  • Stemcell Technologies
  • Miltenyi Biotec
  • Eppendorf
  • Beckman Coulter
  • Takara Bio
  • Bio-Techne
  • PromoCell
  • Wellsky
  • BD
  • Corning Life Sciences
  • HiMedia
  • REPROCELL
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Stem Cell Manufacturing Market

Chapter 4. Global Stem Cell Manufacturing Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Global GDP and Healthcare Infrastructure
    • 4.2.2. Growth in Pharmaceutical, Biotechnology, and CRO/CDMO
    • 4.2.3. Growing Chronic Disease Burden
    • 4.2.4. Transition from Stem Cell Experimental Research to Approved Clinical Therapies
    • 4.2.5. Stem Cell Manufacturing Workflow and Emerging Technologies
      • 4.2.5.1. Embryonic Stem Cells (ESCs)
      • 4.2.5.2. Induced Pluripotent Stem Cells (iPSCs)
      • 4.2.5.3. Adult Stem Cells (ASCs)
    • 4.2.6. Commonly Used Stem Cell Types
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Degree of Competition
  • 4.4. Market Dynamics and Trends
    • 4.4.1. Growth Drivers
    • 4.4.2. Challenges
    • 4.4.3. Opportunity
    • 4.4.4. Key Trends
  • 4.5. Market Growth and Outlook
    • 4.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
    • 4.5.2. Price Trend Analysis
  • 4.6. Competition Dashboard
    • 4.6.1. Market Concentration Rate
    • 4.6.2. Company Market Share Analysis (Value %), 2024
    • 4.6.3. Competitor Mapping & Benchmarking

Chapter 5. Global Stem Cell Manufacturing Market Analysis, By Product Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 5.2.1. Stem Cell Lines
      • 5.2.1.1. Mesenchymal Stem Cells
        • 5.2.1.1.1. Differentiated
          • 5.2.1.1.1.1. Instruments
  • 5.2.1.1.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.1.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.1.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.1.1.2. Consumables and Kits
  • 5.2.1.1.1.2.1. Culture Media
  • 5.2.1.1.1.2.2. Growth Factors & Cytokines
  • 5.2.1.1.1.2.3. Culture ware and Vessels
        • 5.2.1.1.2. Undifferentiated
          • 5.2.1.1.2.1. Instruments
  • 5.2.1.1.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.1.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.1.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.1.2.2. Consumables and Kits
  • 5.2.1.1.2.2.1. Culture Media
  • 5.2.1.1.2.2.2. Growth Factors & Cytokines
  • 5.2.1.1.2.2.3. Culture ware and Vessels
      • 5.2.1.2. Induced Pluripotent Stem Cells
        • 5.2.1.2.1. Differentiated
          • 5.2.1.2.1.1. Instruments
  • 5.2.1.2.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.2.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.2.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.2.1.2. Consumables and Kits
  • 5.2.1.2.1.2.1. Culture Media
  • 5.2.1.2.1.2.2. Growth Factors & Cytokines
  • 5.2.1.2.1.2.3. Culture ware and Vessels
        • 5.2.1.2.2. Undifferentiated
          • 5.2.1.2.2.1. Instruments
  • 5.2.1.2.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.2.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.2.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.2.2.2. Consumables and Kits
  • 5.2.1.2.2.2.1. Culture Media
  • 5.2.1.2.2.2.2. Growth Factors & Cytokines
  • 5.2.1.2.2.2.3. Culture ware and Vessels
      • 5.2.1.3. Hematopoietic Stem Cells
        • 5.2.1.3.1. Differentiated
          • 5.2.1.3.1.1. Instruments
  • 5.2.1.3.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.3.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.3.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.3.1.2. Consumables and Kits
  • 5.2.1.3.1.2.1. Culture Media
  • 5.2.1.3.1.2.2. Growth Factors & Cytokines
  • 5.2.1.3.1.2.3. Culture ware and Vessels
        • 5.2.1.3.2. Undifferentiated
          • 5.2.1.3.2.1. Instruments
  • 5.2.1.3.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.3.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.3.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.3.2.2. Consumables and Kits
  • 5.2.1.3.2.2.1. Culture Media
  • 5.2.1.3.2.2.2. Growth Factors & Cytokines
  • 5.2.1.3.2.2.3. Culture ware and Vessels
      • 5.2.1.4. Embryonic Stem Cells
        • 5.2.1.4.1. Differentiated
          • 5.2.1.4.1.1. Instruments
  • 5.2.1.4.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.4.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.4.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.4.1.2. Consumables and Kits
  • 5.2.1.4.1.2.1. Culture Media
  • 5.2.1.4.1.2.2. Growth Factors & Cytokines
  • 5.2.1.4.1.2.3. Culture ware and Vessels
        • 5.2.1.4.2. Undifferentiated
          • 5.2.1.4.2.1. Instruments
  • 5.2.1.4.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.4.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.4.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.4.2.2. Consumables and Kits
  • 5.2.1.4.2.2.1. Culture Media
  • 5.2.1.4.2.2.2. Growth Factors & Cytokines
  • 5.2.1.4.2.2.3. Culture ware and Vessels
      • 5.2.1.5. Neural Stem Cells
        • 5.2.1.5.1. Differentiated
          • 5.2.1.5.1.1. Instruments
  • 5.2.1.5.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.5.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.5.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.5.1.2. Consumables and Kits
  • 5.2.1.5.1.2.1. Culture Media
  • 5.2.1.5.1.2.2. Growth Factors & Cytokines
  • 5.2.1.5.1.2.3. Culture ware and Vessels
        • 5.2.1.5.2. Undifferentiated
          • 5.2.1.5.2.1. Instruments
  • 5.2.1.5.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.5.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.5.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.5.2.2. Consumables and Kits
  • 5.2.1.5.2.2.1. Culture Media
  • 5.2.1.5.2.2.2. Growth Factors & Cytokines
  • 5.2.1.5.2.2.3. Culture ware and Vessels
      • 5.2.1.6. Others
        • 5.2.1.6.1. Differentiated
          • 5.2.1.6.1.1. Instruments
  • 5.2.1.6.1.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.6.1.1.2. Cell Sorters & Separation Devices
  • 5.2.1.6.1.1.3. Flow Cytometers & Analysers
          • 5.2.1.6.1.2. Consumables and Kits
  • 5.2.1.6.1.2.1. Culture Media
  • 5.2.1.6.1.2.2. Growth Factors & Cytokines
  • 5.2.1.6.1.2.3. Culture ware and Vessels
        • 5.2.1.6.2. Undifferentiated
          • 5.2.1.6.2.1. Instruments
  • 5.2.1.6.2.1.1. Bioreactors & Cell Expansion Systems
  • 5.2.1.6.2.1.2. Cell Sorters & Separation Devices
  • 5.2.1.6.2.1.3. Flow Cytometers & Analysers
          • 5.2.1.6.2.2. Consumables and Kits
  • 5.2.1.6.2.2.1. Culture Media
  • 5.2.1.6.2.2.2. Growth Factors & Cytokines
  • 5.2.1.6.2.2.3. Culture ware and Vessels
    • 5.2.2. Consumables and Kits
      • 5.2.2.1. By Type
        • 5.2.2.1.1. Culture Media
        • 5.2.2.1.2. Growth Factors & Cytokines
        • 5.2.2.1.3. Culture ware and Vessels
          • 5.2.2.1.3.1. T-Flasks
          • 5.2.2.1.3.2. Vials
          • 5.2.2.1.3.3. Cell Culture Dishes / Multi-Well Plates
          • 5.2.2.1.3.4. Cell Culture Bags
          • 5.2.2.1.3.5. Others
        • 5.2.2.1.4. Others
      • 5.2.2.2. By Application
        • 5.2.2.2.1. Research Applications
          • 5.2.2.2.1.1. Disease Modelling
          • 5.2.2.2.1.2. Drug Discovery & Toxicology Testing
          • 5.2.2.2.1.3. Others
        • 5.2.2.2.2. Clinical Applications
          • 5.2.2.2.2.1. Autologous Therapies
          • 5.2.2.2.2.2. Allogeneic Therapies
        • 5.2.2.2.3. Cell & Tissue Banking
    • 5.2.3. Instruments
      • 5.2.3.1. Bioreactors & Cell Expansion Systems
      • 5.2.3.2. Cell Sorters & Separation Devices
      • 5.2.3.3. Flow Cytometers & Analysers
    • 5.2.4. Software and Services

Chapter 6. Global Stem Cell Manufacturing Market Analysis, By Application

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 6.2.1. Research Applications
      • 6.2.1.1. Disease Modelling
      • 6.2.1.2. Drug Discovery & Toxicology Testing
      • 6.2.1.3. Others
    • 6.2.2. Clinical Applications
      • 6.2.2.1. Autologous Therapies
      • 6.2.2.2. Allogeneic Therapies
    • 6.2.3. Cell & Tissue Banking

Chapter 7. Global Stem Cell Manufacturing Market Analysis, By Distribution Channel

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 7.2.1. Direct Sales
    • 7.2.2. Distributors

Chapter 8. Global Stem Cell Manufacturing Market Analysis, By End Users

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 8.2.1. CROs, Pharmaceutical and Biotechnology Companies
    • 8.2.2. Academic & Research Institutions
    • 8.2.3. Hospitals & Surgical Centres
    • 8.2.4. Cell & Tissue Banks
    • 8.2.5. Other Users (Regenerative Medicine Startups, Diagnostic Firms)

Chapter 9. Global Stem Cell Manufacturing Market Analysis, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
      • 9.2.2.1. Western Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Rest of Western Europe
      • 9.2.2.2. Eastern Europe
        • 9.2.2.2.1. Poland
        • 9.2.2.2.2. Russia
        • 9.2.2.2.3. Rest of Eastern Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. South Korea
      • 9.2.3.5. Australia & New Zealand
      • 9.2.3.6. ASEAN
        • 9.2.3.6.1. Cambodia
        • 9.2.3.6.2. Indonesia
        • 9.2.3.6.3. Malaysia
        • 9.2.3.6.4. Philippines
        • 9.2.3.6.5. Singapore
        • 9.2.3.6.6. Thailand
        • 9.2.3.6.7. Vietnam
      • 9.2.3.7. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Rest of South America

Chapter 10. North America Stem Cell Manufacturing Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By End Users
    • 10.2.5. By Country

Chapter 11. Europe Stem Cell Manufacturing Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 11.2.1. By Product Type
    • 11.2.2. By Application
    • 11.2.3. By Distribution Channel
    • 11.2.4. By End Users
    • 11.2.5. By Country

Chapter 12. Asia Pacific Stem Cell Manufacturing Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 12.2.1. By Product Type
    • 12.2.2. By Application
    • 12.2.3. By Distribution Channel
    • 12.2.4. By End Users
    • 12.2.5. By Country

Chapter 13. Middle East & Africa Stem Cell Manufacturing Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 13.2.1. By Product Type
    • 13.2.2. By Application
    • 13.2.3. By Distribution Channel
    • 13.2.4. By End Users
    • 13.2.5. By Country

Chapter 14. South America Stem Cell Manufacturing Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020-2033 (US$ Mn)
    • 14.2.1. By Product Type
    • 14.2.2. By Application
    • 14.2.3. By Distribution Channel
    • 14.2.4. By End Users
    • 14.2.5. By Country

Chapter 15. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 15.1. Thermo Fisher Scientific
  • 15.2. Lonza
  • 15.3. nacalai
  • 15.4. BioRad
  • 15.5. Merck
  • 15.6. FujiFilm
  • 15.7. CellGenix
  • 15.8. Teknova
  • 15.9. Sartorius
  • 15.10. Stemcell Technologies
  • 15.11. Miltenyi Biotec
  • 15.12. Eppendorf
  • 15.13. Beckman Coulter
  • 15.14. Takara Bio
  • 15.15. Bio-Techne
  • 15.16. PromoCell
  • 15.17. Wellsky
  • 15.18. BD
  • 15.19. Corning Life Sciences
  • 15.20. HiMedia
  • 15.21. REPROCELL
  • 15.22. Other Prominent Players

Chapter 16. Annexure

  • 16.1. List of Secondary Sources
  • 16.2. Key Country Markets - Macro Economic Outlook/Indicator